Open Access

Hairy cell leukemia in kidney transplantation: lesson from a rare disorder

  • Fabrizio Vinante1Email author,
  • Paola Tomei2,
  • Gianluigi Zaza2,
  • Alberto Zamò3 and
  • Antonio Lupo2
Experimental Hematology & Oncology20132:22

DOI: 10.1186/2162-3619-2-22

Received: 6 June 2013

Accepted: 2 August 2013

Published: 8 August 2013

Abstract

We report here on the diagnosis and successful treatment of a case of hairy cell leukemia (HCL) that arose 15 years after kidney transplantation in a 51-year-old patient. As soon as the diagnosis was made, HCL was treated with 2-CDA, obtaining complete hematological remission. Immunosuppression with the calcineurin inhibitor cyclosporin was maintained, and the graft was preserved. In kidney transplant recipients supported with immunosuppressive drugs, post-transplant lymphoproliferative diseases (PTLDs) are frequent and typically related to immunosuppression via a loss of control of infectious/EBV-related proliferative stimuli. To date, HCL has not been considered among PTLDs. Recently, however, the oncogenic mutation V600E of the BRAF protein kinase has been found to be a hallmark of HCL, and calcineurin inhibitors have been shown to interfere with signaling downstream of V600E BRAF early on by counteracting senescence-associated mechanisms that protect against the oncogenic potential of the mutated kinase. Such a biochemical link between the oncogene-dependent signaling and calcineurin inhibitor activities suggests that HCL in transplanted patients might be a peculiar type of PTLD based on the presence of a specific mutation. This mechanism might also be involved in other neoplasias bearing the same or similar mutations, such as melanoma and non-melanoma skin cancer.

Keywords

Hairy cell leukemia Kidney transplantation BRAF V600E BRAF Immunosuppression Calcineurin inhibitors Post-transplant lymphoproliferative disease Post-transplant cancer Treatment

Background

Renal transplantation has been a major breakthrough in the treatment of end-stage renal disease, improving quality of life and reducing the mortality risk for most patients when compared with maintenance dialysis [1]. However, the rate of late graft loss remains excessive (10-year survival approximately 50%), primarily due to cardiovascular diseases and neoplasias [2, 3].

Kidney transplant recipients supported with immunosuppressive drugs are approximately three times more likely to develop cancers than the general population. This excess risk is 200 and 9–20 times for Kaposi's sarcoma and nonmelanocytic/melanocytic skin cancer, respectively [4, 5]. Among nonskin cancers, viral infection-related forms are predominant, such as cervical in situ disease, vulvovaginal disease, and the so-called post-transplantation lymphoproliferative diseases (PTLDs), which include Epstein-Barr virus-driven B-cell lymphoproliferation, Hodgkin's lymphoma, multiple myeloma, T/natural killer-cell lymphoproliferation, hepatosplenic γδ T-cell lymphoma and virus-induced hemophagocytic syndrome [57]. Hairy cell leukemia (HCL) is a rare indolent B-cell lymphoproliferative disease that induces severe, life-threatening pancytopenia and is not currently considered a PTLD. One case of HCL, which caused the patient’s death, has been reported following renal transplantation [8], and one other case has been reported in a heart transplant patient [9].

Case presentation

A 51-year-old female was admitted to our renal unit with an 8-week history of severe neutropenia mild anemia and thrombocytopenia. She underwent a cadaveric kidney transplant in 1998 after 2 years of hemodialysis treatment for end-stage renal disease due to chronic tubular-interstitial nephritis. Following transplant, renal function was stable over 15 years with serum creatinine ranging from 106 to 133 μmol/L and no significant daily proteinuria. Maintenance immunosuppressive therapy included cyclosporin (CsA, 60+60 mg/day; C0=88, C2=488 μg/L), methylprednisolone (MP, 4 mg/day) and mycophenolate mofetil (MMF, 1 g/day). MP and MMF were discontinued due to neutropenia, but CsA was maintained.

A physical examination, renal allograft function, abdominal ultrasonography, thoracic Rx and rheumatologic and infectious disease screening were unremarkable. Because the pancytopenia was persistent, peripheral blood and bone marrow examinations were performed. A peripheral blood smear and a flow cytometric study of circulating mononuclear cells failed to show diagnostic cells. Bone marrow could not be aspirated. Biopsy showed severely hypocellular marrow with few infiltrating B cells, which suggested lymphoproliferative disease. A contralateral biopsy showed a pattern of marrow infiltration by mature B lymphocytes that was diagnostic of HCL (Figure  1).
https://static-content.springer.com/image/art%3A10.1186%2F2162-3619-2-22/MediaObjects/40164_2013_Article_59_Fig1_HTML.jpg
Figure 1

Bone marrow biopsy. Infiltrate of mature lymphoid cells (hematoxylin & eosin, H/E), which stained for CD20 (B cell marker), DBA44 and V600E BRAF (HCL markers). Histology and immunohistology were performed according to standard diagnostic procedures.

The severely neutropenic patient was supported with both G-CSF and Epo and underwent ambulatory chemotherapy with the purine analog 2-CDA (2-Chlorodeoxyadenosine, leustatin, cladribine) according to a schedule of 0.1 mg/Kg IV once per week for 4 to 6 weeks. Prophylaxis with sulfamethoxazole-trimethoprim and recommended adequate hydration with crystalloids were performed. The 2-CDA schedule was continued for up to 6 administrations without adverse reactions or infectious complications. Due to an increase in serum creatinine to 199 μmol/L, the fourth administration was delayed one week, and the entire course of therapy lasted 7 weeks. Blood counts reached normal values approximately 2 months after starting 2-CDA. Currently, one year after stopping treatment, the patient is in continuous complete hematological remission with stable renal function (Figure  2). No bone marrow evaluation was performed.
https://static-content.springer.com/image/art%3A10.1186%2F2162-3619-2-22/MediaObjects/40164_2013_Article_59_Fig2_HTML.jpg
Figure 2

Sequential hemochrome and creatinine values in relationship to treatment.

Discussion

Approximately 2% of leukemias in the general population are HCLs, with fewer than 2,000 new cases diagnosed annually in North America and Western Europe combined, and the disease occurs predominantly in older males [10]. After its characterization by Bouroncle and colleagues in 1958 [11], HCL was named after the “hairy” projections observed microscopically on the malignant mature B cells.

Hairy cells progressively infiltrate the bone marrow and spleen, and mild to severe pancytopenia and splenomegaly are frequent features at diagnosis. Although a full-blown leukemic picture is sometimes observed, only scant hairy cells are typically observed in the peripheral blood. High levels of soluble p55-IL-2R [12] and TNFRs [13], shed by the neoplastic cells, are detectable in the serum. TNF appears to play a pathogenic role [14] reminiscent of that in other leukemias [15, 16]. Before the introduction of effective therapy, the median survival was approximately 50 months, and the natural history of HCL was one of progressive splenomegaly, bone marrow failure and death, typically due to infection. Alpha-interferon was the first treatment to obtain full remission of disease [12]. Subsequently, a variety of systemic agents have been used. 2-CDA is the preferred front-line therapy to date and is capable of inducing durable clinical remission in the majority of cases, although it fails to be curative [17, 18].

Due to deep neutropenia and monocytopenia (Figure  2), HCL patients are prone to life-threatening infections, including atypical mycobacteriosis and aspergillosis. There are two relevant risks with HCL in transplant patients: life-threatening sepsis due to severe neutropenia and immunosuppression and the risk of graft loss due to either sepsis or deferred immunosuppression. Therefore, we started treatment early after diagnosis [18]. Erythropoietin and granulocyte colony stimulating factor allowed for the maintenance of adequate hemoglobin and white blood cell counts and most likely made it easier to avoid infection and complete the entire course of therapy with 2-CDA. We maintained CsA to preserve the transplant.

The pathogenesis of post-transplantation malignancies appears to be related to immunosuppression, leading to impaired immune activity against viruses, impaired immunosurveillance of neoplastic cells, DNA damage and disruption of DNA repair mechanisms and the upregulation of cytokines that can promote tumor progression (e.g., TNF, TGFβ, IL-10, VEGF). HCL is not currently considered a post-transplantation malignancy related to immunosuppression [19], but a coincidental event in a transplant patient.

Recently, however, the V600E mutation of the BRAF kinase protein (Figure  1), previously described in moles [20], melanoma and other cancers [21, 22], has been recognized to be present in the majority of typical HCL cases [23]. The mutation results in the constitutive activity of BRAF kinase, which in turn triggers the Ras pathway, AP-1 and NFAT to promote cell growth [22, 24]. Constitutively activated BRAF may trigger senescence, which neutralizes the mitogenic potential of BRAF [20]. Secondary events, however, may restore the full mitogenic potential of BRAF and induce lesion progression to overt cancer [20, 25, 26]. Calcineurin inhibitors such as CsA and tacrolimus participates in the BRAF pathway, and reduce the amount of message converging on NFAT downstream mutated BRAF [24, 2730]. By doing this, calcineurin inhibitors may counteract V600E BRAF-dependent senescence and increase the tumorigenic potential of senescent lesions [20, 25, 26, 31].

Therefore, HCL harbors a mutated form of BRAF protein kinase [23] that results in constitutive signaling involved in oncogenesis [20, 21, 2632], and calcineurin inhibitors play a part in this signaling [21, 22, 2434]. This direct link between immunosuppression and a typical oncogenic feature of HCL may suggest that HCL could be considered a PTLD instead of a merely coincidental event in a host treated with calcineurin inhibitors, although it may be a peculiar PTLD entailing the V600E BRAF protein kinase mutation and most likely additional events [20, 25, 26, 31].

Paradoxically, calcineurin inhibitors may also counteract the constitutive BRAF-driven mitogenic activity in overt cancer [25, 2831], based on the same biochemical mechanism [24, 25, 31, 32]. Therefore, inhibitors of BRAF signaling may have the opposite effects depending on whether the V600E BRAF-bearing cells are senescent [20, 25, 26] or cancerous [2830, 3234]. This duality may explain why melanomas harboring the V600E mutation of BRAF are quite frequent in transplant patients immunosuppressed with calcineurin inhibitors [4, 5, 21] as well as why BRAF inhibitors may have a place in melanoma treatment [21, 27, 3034].

Our results suggest the following conclusions: 1) Persistent pancytopenia in a transplant patient requires timely and thorough consideration. 2) HCL should be treated as soon as possible in transplanted patients, and 2-CDA may be a good therapeutic option to induce disease remission and avoid life-threatening infection and graft loss. 3) The occurrence of a direct link between oncogenic pathways and calcineurin inhibitors in V600E BRAF-bearing cells may perhaps suggest that HCL could be included among PTLDs, although HCL might be a peculiar PTLD based on the presence of a specific mutation. 4) In general, immunosuppressive drugs may target mutation-activated oncogenic pathways to promote cancer.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

HCL: 

Hairy cell leukemia

2-CDA: 

2-Chlorodeoxyadenosine

PTLD: 

Post-transplant lymphoproliferative disease

CsA: 

Cyclosporin A

MP: 

Methylprednisolone

MMF: 

Mycophenolate mofetil

Hb: 

Hemoglobin

WBC: 

White blood cells

PMN: 

Neutrophils

Mono: 

Monocytes

Plts: 

Platelets

p55-IL-2R: 

Low-affinity receptor for interleukin 2

TNFR: 

Receptor for tumor necrosis factor

IL-10: 

Interleukin 10

TGFβ: 

Transforming growth factor β

VEGF: 

Vascular endothelial growth factor

BRAF: 

V-raf murine sarcoma viral oncogene homolog B encoding the serine/threonine-specific protein kinase B-Raf

V600E BRAF: 

BRAF mutant that leads to valine (V) being substituted for by glutamate (E) at codon 600 in the protein kinase B-Raf

Ras: 

Small proteins with GTPase activity that activate B-Raf

AP-1: 

Activator protein 1, dimeric transcription factors including Fos, Jun or ATF (activating transcription factor) subunits that bind to a common DNA site, the AP-1-binding site

NFAT: 

Nuclear factor of activated T-cells, collective name applied to a family of transcription factors important in immunity.

Declarations

Acknowledgement

This work was supported by grants from the Italian Association for Cancer Research (AIRC, Milan, Italy)/Cariverona Foundation (Verona, Italy).

Authors’ Affiliations

(1)
Section of Hematology, Department of Medicine, University of Verona
(2)
Renal Unit, Department of Medicine, University Hospital of Verona
(3)
Section of Pathological Anatomy, Department of Pathology and Diagnostics, University of Verona

References

  1. Van Der Woude FJ: Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998, 9: 2135–2141.PubMedGoogle Scholar
  2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000, 342: 605–612. 10.1056/NEJM200003023420901PubMedView ArticleGoogle Scholar
  3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4: 378–383. 10.1111/j.1600-6143.2004.00332.xPubMedView ArticleGoogle Scholar
  4. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant 2004, 4: 905–913. 10.1111/j.1600-6143.2004.00450.xPubMedView ArticleGoogle Scholar
  5. Vajdic CM, McDonald SP, McCredie MR, Van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE: Cancer incidence before and after kidney transplantation. JAMA 2006, 296: 2823–2831. 10.1001/jama.296.23.2823PubMedView ArticleGoogle Scholar
  6. Marinella MA: Hematologic abnormalities following renal transplantation. Int Urol Nephrol 2010, 42: 151–164. 10.1007/s11255-009-9558-5PubMedView ArticleGoogle Scholar
  7. Caillard S, Agodoa LY, Bohen EM, Abbott KC: Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006, 81: 888–895. 10.1097/01.tp.0000203554.54242.56PubMedView ArticleGoogle Scholar
  8. Mamzer-Bruneel MF, Legendre C, Hermine O, Flandrin G, Varet B, Kreis H: Hairy-cell leukaemia in a renal transplant recipient. Nephrol Dial Transplant 1996, 11: 2088–2089. 10.1093/oxfordjournals.ndt.a027106PubMedView ArticleGoogle Scholar
  9. Tsao L, Chu EK, Bhagat G, Alobeid B: Development of hairy cell leukemia in a patient after cardiac transplantation. Leuk Lymphoma 2006, 47: 361–363. 10.1080/10428190500254505PubMedView ArticleGoogle Scholar
  10. Staines A, Cartwright RA: Hairy cell leukaemia: descriptive epidemiology and a case–control study. Br J Haematol 1993, 85: 714–717. 10.1111/j.1365-2141.1993.tb03213.xPubMedView ArticleGoogle Scholar
  11. Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticuloendotheliosis. Blood 1958, 13: 609–630.PubMedGoogle Scholar
  12. Chilosi M, Semenzato G, Cetto G, Ambrosetti A, Fiore-Donati L, Perona G, Berton G, Lestani M, Scarpa A, Agostini C, Trentin L, Zambello R, Masciarelli M, Dazzi F, Vinante F, Caligaris-Cappio F, Pizzolo G: Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987, 70: 1530–1535.PubMedGoogle Scholar
  13. Trentin L, Pizzolo G, Zambello R, Agostini C, Morosato L, Sancetta R, Adami F, Vinante F, Chilosi M, Gallati H, Semenzato G: Leukemic cells in hairy-cell leukemia and B-cell chronic lymphocytic-leukemia release soluble TNF receptors. Leukemia 1995, 9: 1051–1055.PubMedGoogle Scholar
  14. Trentin L, Zambello R, Pizzolo G, Vinante F, Ambrosetti A, Chisesi T, Vespignani M, Feruglio C, Adami F, Agostini C, Semenzato G: Tumor-necrosis-factor-alpha and B-cell growth-factor induce leukemic hairy-cells to proliferate in vitro. Cancer Detect Prev 1991, 15: 385–390.PubMedGoogle Scholar
  15. Vinante F, Rigo A, Tecchio C, Morosato L, Nadali G, Ricetti MM, Krampera M, Zanolin E, Locatelli F, Gallati H, Chilosi M, Pizzolo G: Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome. Br J Haematol 1998, 102: 1025–1034. 10.1046/j.1365-2141.1998.00872.xPubMedView ArticleGoogle Scholar
  16. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR: Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010, 116: 4251–4261. 10.1182/blood-2010-01-262071PubMed CentralPubMedView ArticleGoogle Scholar
  17. Robak T, Robak P: Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des 2012, 18: 3373–3388. 10.2174/138161212801227005PubMedView ArticleGoogle Scholar
  18. Naik RR, Saven A: My treatment approach to hairy cell leukemia. Mayo Clin Proc 2012, 87: 67–76. 10.1016/j.mayocp.2011.09.001PubMed CentralPubMedView ArticleGoogle Scholar
  19. Domhan S, Zeier M, Abdollahi A: Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant 2009, 24: 1097–1103.PubMedView ArticleGoogle Scholar
  20. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, Van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436: 720–724. 10.1038/nature03890PubMedView ArticleGoogle Scholar
  21. Pakneshan S, Salajegheh A, Smith RA, Lam AK: Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013, 45: 356–356.View ArticleGoogle Scholar
  22. Huang T, Karsy M, Zhuge J, Zhong M, Liu D: B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 2013, 6: 30. 10.1186/1756-8722-6-30PubMed CentralPubMedView ArticleGoogle Scholar
  23. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B: BRAF mutations in hairy-cell leukemia. N Engl J Med 2011, 364: 2305–2315. 10.1056/NEJMoa1014209PubMed CentralPubMedView ArticleGoogle Scholar
  24. Dhomen N, Marais R: New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007, 17: 31–39. 10.1016/j.gde.2006.12.005PubMedView ArticleGoogle Scholar
  25. Wu X, Nguyen BC, Dziunycz P, Chang S, Brooks Y, Lefort K, Hofbauer GF, Dotto GP: Calcineurin and ATF3: opposite roles in squamous skin cancer. Nature 2010, 465: 368–372. 10.1038/nature08996PubMed CentralPubMedView ArticleGoogle Scholar
  26. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012, 26: 1055–1069. 10.1101/gad.187252.112PubMed CentralPubMedView ArticleGoogle Scholar
  27. Medyouf H, Ghysdael J: The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle 2008, 7: 297–303. 10.4161/cc.7.3.5357PubMedView ArticleGoogle Scholar
  28. Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE: NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br J Cancer 2009, 101: 1448–1455. 10.1038/sj.bjc.6605277PubMed CentralPubMedView ArticleGoogle Scholar
  29. Buchholz M, Ellenrieder V: An emerging role for Ca2+/calcineurin/NFAT signaling in cancerogenesis. Cell Cycle 2007, 6: 16–19. 10.4161/cc.6.1.3650PubMedView ArticleGoogle Scholar
  30. Halilovic E, Solit DB: Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 2008, 8: 419–426. 10.1016/j.coph.2008.06.014PubMedView ArticleGoogle Scholar
  31. Warfel NA, El-Deiry WS: p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 2013, 25: 52–58. 10.1097/CCO.0b013e32835b639ePubMedView ArticleGoogle Scholar
  32. Weeraratna AT: RAF around the Edges — the paradox of BRAF inhibitors. N Engl J Med 2012, 366: 271–273. 10.1056/NEJMe1111636PubMedView ArticleGoogle Scholar
  33. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, Dong C, Robertson GP: Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 2006, 66: 8200–8209. 10.1158/0008-5472.CAN-06-0809PubMed CentralPubMedView ArticleGoogle Scholar
  34. Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, Dal Col J, Dolcetti R, Anichini A, Mortarini R: NFATc2 is a potential therapeutic target in human melanoma. J Invest Dermatol 2012, 132: 2652–2660. 10.1038/jid.2012.179PubMedView ArticleGoogle Scholar

Copyright

© Vinante et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement